Table 3.
Andersen-Gill regression model with the endpoint EFS analysed on an intention-to-treat basis
| HR | 95 % CI | p value | |
|---|---|---|---|
| Genetic risk according to ELN | |||
| Favorable risk’ | 0.38 | 0.31–0.47 | <0.0001 |
| Intermediate-2’ | 1.05 | 0.86–1.30 | 0.62 |
| Adverse-risk’ | 1.80 | 1.48–2.18 | <0.0001 |
| s/t-AML | 1.28 | 1.04–1.57 | 0.020 |
| Gender (male) | 1.35 | 1.17–1.56 | <0.0001 |
| WBC (Median-dichotomized)* | 1.29 | 1.11–1.49 | 0.001 |
| Valproic acid | 1.22 | 1.02–1.47 | 0.032 |
| Allogeneic HCT in 1st CR | 0.47 | 0.38–0.60 | <0.0001 |
| ATRA | 0.99 | 0.86–1.14 | 0.87 |
Variables excluded after limited backward selection in the order of their exclusion: DNMT3A mutational status (p = 0.82), ASXL1 mutational status (p = 0.70), RUNX1 mutational status (p = 0.56), FLT3-TKD (p = 0.48), IDH2 mutational status (p = 0.39), IDH1 mutational status (p = 0.32) and age (p = 0.10)
*The median WBC of the whole cohort was 12.7 G/L